Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NEW JERSEY, the U.S. and HANGZHOU, China, Sep 8, 2021 – (ACN Newswire via SEAPRWire.com) – Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced […]